Findings presented at the 2025 ADHD World Congress in Prague highlight the benefits of QbCheck, Qbtech’s remote testing solution, in enhancing diagnostic accuracy and individualizing treatment monitoring for ADHD, particularly in virtual settings. A new study conducted with ADHD 360, the UK’s largest evidence-based digital service specializing in ADHD diagnosis and treatment, demonstrates that objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty.

The study underscores the importance of using scalable, evidence-based tools to address the rising demand for ADHD diagnosis and treatment in countries like the UK and the US. It reveals that QbCheck enables clinicians to make more confident, data-informed decisions, fostering a more personalized and collaborative care model. The tool provides greater clarity in assessing symptoms and adjusting treatment plans, which ensures diagnostic accuracy and improves alignment between clinicians and patients throughout their care journey.

ADHD 360’s implementation of this model showcases how a standardized approach to virtual ADHD care enhances clinician confidence, reduces wait times, and increases patient engagement. QbCheck is used not only as a diagnostic tool but also to monitor the effects of treatment, allowing clinicians to adjust treatment plans as necessary. Carl Ellis, Mental Health Nurse and Team Manager at ADHD 360, emphasizes that QbCheck ensures every patient is assessed using the same evidence-based criteria, minimizing subjective bias and enabling the delivery of reliable, high-quality care at scale.

The study results indicate significant improvements from baseline to post-treatment assessments. Beyond its use as an objective symptom measurement and diagnostic tool, QbCheck highlights patient response to pharmacological treatment, which supports clinicians in creating individualized and adaptive treatment plans by providing quantifiable data on symptom presentation and response. Data was collected from routine QbCheck assessments within the ADHD 360 model in the UK, with baseline data collected before diagnosis and treatment, and additional assessments administered after patients were optimized with stimulant medication treatment. In addition to QbCheck, patients were assessed using the Adult ADHD Self Report Scale (ASRS), the Swanson, Nolan and Pelham Rating Scale (SNAP), and the QbCheck Rating Scale (QbRS) to assess self-reported symptoms.

Dr. Mikkel Hansen, Chief Medical Officer at Qbtech, notes that QbCheck brings transparency and structure to the process, enabling clinicians to visualize symptoms clearly, track treatment response, and provide patients with objective validation. The data demonstrates how a standardized pathway to virtual ADHD care helps clinicians facilitate remote monitoring of medication treatment effects, symptom regulation, and overall treatment outcomes, which are essential for virtual care models like ADHD 360.

Given the increasing scrutiny of ADHD care and the expansion of virtual care models, QbCheck is recognized for its clinical rigor, patient-centered design, and scalability. First developed in 2016, QbCheck enhances the clinician and patient experience to ensure optimal care in virtual settings. It is used by over 10,000 clinicians worldwide, in both virtual and brick-and-mortar clinics offering remote ADHD services, providing equitable access to care, especially for those in mental health provider shortage areas. Since its launch in Sweden in 2002, Qbtech has supported more than 1 million patients globally.

More than 40 independent studies document the company’s benefits across the patient care pathway, including improved access to care, elevated clinician confidence, a 50% better indication of treatment effects than standardized self-rating scales, and consistency of care across multiple disciplines. Founded in 2002, Qbtech has operations in 14 countries with offices in Stockholm, Houston, and London, and has been recognized for its innovation, including the 2022 HSJ Partnership Award for the ‘Best Mental Health Partnership with the NHS.’